Neurogenic
Neurogenic is a clinical-stage diagnostics company advancing the development of a novel ELISA-based immunoassay to detect pathological Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients to facilitate the diagnosis of early-onset schizophrenia.
Neurogenic's proprietary reagents and diagnostic assay are protected by a series of worldwide issued patents and pending patent applications.
The company is conducting a clinical trial entitled Collection and Analysis of Blood Samples from Children and Adolescents Experiencing Initial Symptoms of Acute Mental Illness to Develop an ELISA-based Diagnostic Assay to Aid in the Diagnosis of Schizophrenia in collaboration with Beer Yaakov-Ness Ziona Mental Health Center.
Two analytical versions of the diagnostic assay have been developed, one employing the Horseradish Peroxidase (HRP) detection reagent and the other employing the Protein G detection reagent.
A novel monoclonal antibody control has been produced and integrated into the assay procedure.
The Standard Operating Procedures (SOPs) for the HRP and Protein G assays are now being finalized.
For more information, please contact:
Dr. Yechiel Goldman, Ph.D.
Scientific Writer, Consultant
Bikorei HaKerem Regulatory & Scientific Writing
T: +972-54-200-3128
Mr. Yossi Avnat, M.A.
Director
Neurogenic Ltd.
T: +972-3-510-1992